This study is looking at whether Valsartan, a medication already used for high blood pressure and heart failure, can help people with pulmonary arterial hypertension (PAH). PAH is a condition where blood pressure in the arteries of your lungs is too high, which can strain the right side of your heart. Currently, there are no medications that directly improve right heart function in PAH. This study will compare Valsartan to a placebo (an inactive substance) over 24 weeks to see if Valsartan is safe and effective in improving right heart function. You may be able to join if you are between 18 and 80 years old, have WHO Group 1 PAH, and meet certain heart function criteria. The main way we'll know if the treatment is successful is by measuring how far you can walk in six minutes.

Study design

This is a Phase 2, single-center study where participants will be randomly assigned to receive either Valsartan or a placebo. The study plans to enroll 60 adults.

What's involved

You will take Valsartan or placebo twice daily for 24 weeks. You will have three study visits at 0, 2, 12, and 24 weeks, which will add 20-30 minutes to your standard clinic visits. You will also have an echocardiogram at weeks 0 and 24.

Compensation

Not stated in the trial record.

Follow-up

Participants are followed for 24 weeks, which is the duration of the intervention and the primary endpoint measurement period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.